directed evolution of enantioselective biocatalysts · directed evolution of baeyer villigerases...

28
Directed Evolution of Stereoselective Biocatalysts David Knapp CHEM575 Literature Seminar 3-13-2008

Upload: others

Post on 09-Jul-2020

13 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Directed Evolution of Stereoselective Biocatalysts

David KnappCHEM575 Literature Seminar

3-13-2008

Page 2: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Importance of Stereoselective Synthesis

Page 3: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Catalytic Approaches

Small Molecules Enzymes

•High substrate scope•Stability/Solubility•Synthetic accessibility•Decades of development

•Poor solubility/stability•Greener chemistry•Tremendous complexity•Excellent stereoselectivity

Page 4: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

How can we get better enzymatic catalysts?

Cloning naturalenzymes De novo design

Rational modification

Directed evolution

Page 5: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Directed Evolution

RandomMutagenesis

Transformation &Expression

Selection /Screening

Cloned DNA

Page 6: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Mutagenesis Methods

DNA Shuffling

Error Prone PCR (epPCR)Taq

MnCl2Cloned DNA

Cadwell, R. C.; Joyce, G. F. PCR Methods Appl. 1994, 3, 136-140.Soi, C. F.; et al. Eur. J. Biochem. 2002, 269, 4495-4504.Stemmer, W. P. C. Proc. Natl. Acad. Sci. 1994, 91, 10747-10751.

Primer

Site Saturation MutagenesisRandomizedPrimers

*

Page 7: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

The Sorting Problem

SelectionScreeningEfficientScalableNot SimpleNot General

Brute ForceTime/Labor/Resource IntensiveSimpleGeneral

Large Libraries:Good for diversity, Bad for sorting

Taylor, S. V.; Kast, P; Hilvert, D. Angew. Chem. Int. Ed. 2001, 40, 3310-3335.

Page 8: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Solutions to the Sorting ProblemSelection

Water insoluble Water soluble

Taylor, S. V.; Kast, P; Hilvert, D. Angew. Chem. Int. Ed. 2001, 40, 3310-3335.Reetz, M. T. Angew. Chem. Int. Ed. 2001, 40, 284-310.

Chorismate Mutase Libraries expressed in cells lacking Chorismate Mutase

prephenate

Page 9: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Solutions to the Sorting Problem

SpectroscopyUV-visFluorescence

Chiral ChromatographyHPLCGC

Capillary ElectrophoresisInfrared Thermogenic ImagingCircular DichroismMass Spectrometry

Screening

Reetz, M. T. Angew. Chem. Int. Ed. 2001, 40, 284-310.

• Involves analysis of reaction products

• Throughput is key!

Page 10: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Successful examples

Page 11: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Baeyer Villiger Oxidation

Reetz, M. T., et. al. Angew. Chem. Int. Ed. 2004, 43, 4075-4078.

Mechanism

Chiral Products

Page 12: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Enzymatic Baeyer Villiger Oxidation

Reetz, M. T., et al. Angew. Chem. Int. Ed. 2004, 43, 4075-4078.

Cyclohexanone Monooxygenase (CHMO)

Page 13: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Directed Evolution of Baeyer Villigerases

• Mutagenesis StrategyepPCR – 10,000 in round 1

2,000 in round 2

• ScreeningChiral GC – 800 variants/day

• Libraries expressed in E. coli.

• Screen reaction run with whole cells

Reetz, M. T., et al. Angew. Chem. Int. Ed. 2004, 43, 4075-4078.

Page 14: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Directed Evolution of Baeyer Villigerases

Reetz, M. T., et al. Angew. Chem. Int. Ed. 2004, 43, 4075-4078.

First round hits

O

OH

O2

CHMOmutants

OO

H OH

(R)-3OO

H OH

(S)-3

+

Page 15: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Results of Directed Evolution

Reetz, M. T., et al. Angew. Chem. Int. Ed. 2004, 43, 4075-4078.

Improved R Variant

Substrate Scope

Page 16: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Conclusions from Reetz Study

How is this study significant?

•Unselective enzyme made synthetically useful •Significant reversal of stereoselectivity• Simplistic mutagenic strategy• Substrate scope• Prior knowledge requirements•Superiority to other approaches

Page 17: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

N-acetylneuraminic lyase (NAL)

Williams, G. J., et al. J. Am.. Chem. Soc. 2006, 128, 16238-16247.

Sialic acidsWild type NAL (S:R) = 74:26

(Aldolase)

Page 18: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Directed Evolution of NAL

Williams, G. J., et al. J. Am.. Chem. Soc. 2006, 128, 16238-16247.

• Mutagenesis StrategyepPCR – 2500/roundsite-saturation mutagenesissemi-rational design

• Screening

Pr2NO

OH

OH

OMe CO2

OO

OAcHN

OH

CO2

OHPr2N O

OAcHN

OH

CO2Pr2N

OH

++

lactatedehydrogenase

NADHNAD+

Me CO2

OH+

NAL

variant

Page 19: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Structural Considerations

Williams, G. J., et al. J. Am.. Chem. Soc. 2006, 128, 16238-16247.

4R-selectiveRed

4S-selectiveGreen

Page 20: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Directed Evolution of NAL

Williams, G. J., et al. J. Am.. Chem. Soc. 2006, 128, 16238-16247.

4S-product4R-productaldehyde

Best4S-Selective

Best4R-Selective

66% Yieldd.r. >98:2

70% Yieldd.r. >98:2

Page 21: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Structural Considerations

Williams, G. J., et al. J. Am.. Chem. Soc. 2006, 128, 16238-16247.

4R-selectiveE192NT167VS208V

4S-selectiveE192NT167G

Substrate analog

Page 22: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Evolution of an Enantioselective Aldolase

deoxy-D-ribose 5-phosphate aldolase (DERA)

Proposed Application

• e.r. > 99.9:0.1• Low activity• Limited substrate scope• Substrate Inhibition

Lys

Gijsen, H. J. M.; Wong, C. H. J. Am. Chem. Soc. 1994, 116, 8422‐8423.Greenberg, W. A., et al. PNAS 2004, 101, 5788‐5793.

Page 23: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Directed Evolution of an EnantioselectiveAldolase

•GoalsImprove the activity of DERADecrease substrate inhibition

•Mutagenesis StrategyepPCR – 3,000 clones per roundDNA Shuffling of best hits

• ScreeningTarget reaction run in cell free extractActivity determined by GCThroughput: 300 samples/day

Jennewein, S., et al. Biotechnol. J. 2006, 1, 537-548.

Page 24: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Results of Directed Evolution

Best Hits Displayed:• Increased activity• Reduced substrate inhibition

Jennewein, S., et al. Biotechnol. J. 2006, 1, 537-548.

Page 25: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

DE of an Enantioselective Aldolase

Jennewein, S., et al. Biotechnol. J. 2006, 1, 537-548.

Page 26: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Atorvastatin (Lipitor)

N OH

OOHOHMeMe

O

NH

F

N OH

OOHOHMeMe

O

NH

F

•Statin•Inhibits HMG-CoA-Reductase•Marketed by Pfizer•2006 Sales: $12.9 billion

Hu, S.; Tao, J.; Xie, Z. PCT Int. Appl. 2006, 34pp, WO 2006134482 A1.“Pfizer wins Lipitor Patent Extension”, myiRIS, 4-3-2007.

Single-Enantiomer Synthesis

Page 27: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

Conclusions

Directed Evolution stands as an underutilized, yet potentially general and powerful way to access stereoselective catalysts

BenefitsExceptional catalyst stereoselectivityMethodological complementarity to transition metalsStrategic generalityGreen chemistry

LimitationsCurrent enzymatic scope/availabilityOverhead

Future Directions

Page 28: Directed Evolution of Enantioselective Biocatalysts · Directed Evolution of Baeyer Villigerases • Mutagenesis Strategy epPCR – 10,000 in round 1 2,000 in round 2 • Screening

• Professor Silverman• Professor Burke• The Burke Group• CHEM575 Class

Acknowledgements